Mir 17 5p inhibitor

Manufactured by RiboBio

Sourced in China

The MiR-17-5p inhibitor is a laboratory reagent designed to inhibit the expression of the microRNA miR-17-5p. It is used in research applications to study the biological functions and regulatory roles of miR-17-5p in various cellular and molecular processes.

Automatically generated - may contain errors

Lab products found in correlation

Lipofectamine 3000, by Thermo Fisher Scientific (4 mentions) Mir 17 5p mimic, by RiboBio (1 mentions) Rpmi 1640 medium, by Thermo Fisher Scientific (1 mentions) Mirna mimics nc, by RiboBio (1 mentions) Lipofectamine 3000 transfection reagent, by Thermo Fisher Scientific (1 mentions) Liposome 3000, by Thermo Fisher Scientific (1 mentions) Pcdna nc, by GenePharma (1 mentions) Fast mutagenesis kit, by Vazyme (1 mentions) Psicheck 2 plasmid, by Promega (1 mentions) Pten sirna, by GenePharma (1 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions) Pcdna3.1 vector, by Thermo Fisher Scientific (1 mentions)

4 protocols using mir 17 5p inhibitor

Investigating miR-17-5p and TXNIP in HTR-8/SVneo cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

HTR-8/SVneo cell line was purchased from Servicebio Technology (Wuhan, China). HTR-8/SVneo cells were cultured in RPMI 1640 medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) at 37°C with 5% CO2.
miR-17-5p mimic, miR-17-5p mimic NC, miR-17-5p inhibitor and miR-17-5p inhibitor NC were purchased from RiboBio (Guangzhou, China). TXNIP Vector and Vector NC were purchased from Vigene Biosciences Inc. (Jinan, China). HTR8/SVneo cells were transfected with Lipofectamine^® 3000 (Thermo Fisher Scientific, USA) transfection reagents when reached 50–60% density.

Jiang Y., Wei L., Zhang H., Chen Y., Gao P., Zhang J., Zhou X., Zhu S., Du Y., Fang C., Li J., Feng L., He M., Wang S, & Yu J. (2022). miR-17-5p Promotes Glucose Uptake of HTR8/SVneo Trophoblast Cells by Inhibiting TXNIP/NLRP3 Inflammasome Pathway. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 3361-3374.

+ Open protocol

+ Expand

Modulation of TXNIP-NLRP3 Inflammasome by miR-17-5p

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 1 × 10⁶ ADSCs were cultured in 10 mL of ADSC-conditioned medium overnight before miRNA transfection. ADSCs were then transfected with 10 nM of miR-17-5p inhibitor (RiboBio) and 10 nM of miRNA inhibitor negative control (NC) (RiboBio) by using Lipofectamine® 3000 (#L3000015, Thermo Fisher). To further investigate the role of miR-17-5p in the activation of TXNIP-NLRP3 inflammasome, ADSCs were transfected with miR-17-5p mimics (RiboBio) and 10 nM of miRNA mimics NC (RiboBio) using Lipofectamine® 3000 transfection reagent (#L3000015, Thermo Fisher). At 48 h post-transfection, ADSCs supernatant from each group was harvested for exosome isolation.

Hu J., Jiang Y., Wu X., Wu Z., Qin J., Zhao Z., Li B., Xu Z., Lu X., Wang X, & Liu X. (2022). Exosomal miR-17-5p from adipose-derived mesenchymal stem cells inhibits abdominal aortic aneurysm by suppressing TXNIP-NLRP3 inflammasome. Stem Cell Research & Therapy, 13, 349.

+ Open protocol

+ Expand

Transfection of CD133+CD44+ Colorectal Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were seeded into 6-well plates 24 h before transfection. When the cell confluence reached about 50%, CD133⁺CD44⁺HCT116 cells were transfected with miR-17-5p-negative control (NC), miR-17-5p mimic, or miR-17-5p inhibitor (RiboBio Co., Ltd., Guangdong, China) using Liposome 3000 (Thermo Fisher Scientific, MA, USA). pcDNA-NC and pcDNA-SPOP plasmids constructed by GenePharma (Shanghai, China) were transfected into HCT116 cells. The medium was replaced 6 h later. After 48-h transfection, cells were collected for follow-up experiments.

Sun W., Cui J., Ge Y., Wang J., Yu Y., Han B, & Liu B. (2022). Tumor stem cell-derived exosomal microRNA-17-5p inhibits anti-tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD-L1. Cell Death Discovery, 8, 223.

+ Open protocol

+ Expand

PTEN Regulation by miR-17 in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

For gene knockdown experiments, PTEN siRNA (sense: CGCCAAAUUUAAUUGCAGATT; anti-sense: UCUGCAAUUAAAUUUGGCGTT) and negative control siRNA were obtained from GenePharma (Shanghai, China). For gene overexpression vector construction, the open reading frames and downstream 3'-UTR of PTEN were cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) between the HindIII and EcoRI sites and driven by the cytomegalovirus promoter. For the luciferase reporter assay, the 3'-UTR fragment of PTEN was ampli ed and cloned into the XhoI and NotI sites downstream of the SV40 promoterdriven Renilla luciferase cassette in the psiCHECK-2 plasmid (Promega, Madison, WI, USA). A Fast Mutagenesis kit (Vazyme Biotech, Nanjing, China) was used to mutate the miR-17 binding sites in the PTEN 3'-UTR vectors according to the manufacturer's instructions.
Transient transfection of miRNA MDA-MB-231 cells were seeded in 6-cm cell culture dishes at 1.2×10 5 cells/mL. The cells were transfected with a 50 nM miR-17-5p mimic, miR-17-5p inhibitor or the corresponding scrambled NC (Ribobio, Guangzhou, China) with lipofectamine 2000 (Invitrogen) per the manufacturer's instructions.
After 24 h, the medium was replaced and the cells were prepared for subsequent experiments.

Bao C., Liu T., Qian L., Xiao C., Zhou X., Ai H., Wang S., Fan W., & Pan J. (2020). Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!